Is adjuvant chemotherapy by continuous infusion 5-fluorouracil plus daily low dose cisplatin useful in advanced (stageIV) pancreatic cancer?

Tumor Research

Volumn 32, Issue , 1997, Pages 23-31

  Oikawa, Ikuo ^a   Hirata, Koichi ^a   Hata, Fumitake ^a   Katsuramaki, Tadashi ^a   Mukaiya, Mitsuhiro ^a   Sasaki, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Advanced pancreatic cancer; Biochemical modulation; Cisplatin

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PANCREAS CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0031462082     PISSN: 00414093     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA. Pancreaticoduodenectomy for cancer of the head of the pancreas : 201 patients. Ann Surg 1995, 221:721-733.
2. Moossa AR, Lewis MH, Mackie CR. Surgical treatment of pancreatic cancer. Mayo Clin Proc 1979, 54:468-474.
3. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer - local or hepatic ?. Hepato-Gastro-enterol 1993, 40:384-387.
4. Wils J, Bleiberg H, Bilham G. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin 1985, 21:191-194.
5. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas : comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:3479-3482.
6. Rooney M, Kish J, Jacob J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985, 55:1123-1128.
7. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986, 83:8923-8925.
8. Japan Pancreas Society (1993) General Rules for the Study of Pancreatic Cancer, 4th edn. Kanehara Shuppan, Tokyo.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting of results of cancer treatment. Cancer 1981, 47:207-214.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958, 63:457-481.
11. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965, 52:203-223.
12. Cox DR. Regression models and life tables [with discussion] . J R Stat Soc Ser B 1972, 34:187-220.
13. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. Am J Surg 1986, 151:76-80.
14. Shirasaka T, Shimamoto Y, Ohshima H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor models in vivo. Cancer Chemother Pharmacol 1993, 32:167-172.
15. MacMillan WE, Wobery WH, Welling PG. Pharmacokinetics of 5-fluorouracil in human. Cancer Res 1978, 38:3479-3482.
16. Richard MH, Louise R, Tom A, Beth K, Edward Q, Douglass CT. PhaseIIIstudy of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996, 88:668-674.
17. Takahashi A, Takagi M, Hishida H, Saji E, Takagi N, Amano H. The pharmacokinetics of cisplatin and its influence on renal function according to different infusion methods. Jpn J Cancer Chemother 1987, 14:2944-2950.
18. Mashiba H, Okamoto K, Kobayashi T, Sasaki T, Ekimoto H. Antitumor activity of daily low dose cisplatin treatment against human lung cancer xerografts in nude mice and toxicity in mice. Clin Rep 1993, 27:3135-3146.